

**Richard R. Pleak, MD**

Senior Advisor, Child &  
Adolescent Psychiatry Fellowship  
Zucker Hillside Hospital

Associate Professor  
Psychiatry  
Zucker School of Medicine

**Kathy Pignatelli****Eva Vergara**

Training Program Administrators


11 March 2025

To: WHO Expert Committee on Selection and Use of Essential Medicines

Re: Invitation for public comment for application of methylphenidate in the WHO Essential Medicines List, **A.19 Methylphenidate – attention deficit hyperactivity disorder**

I enthusiastically support the appeal in reference to the application “A.19 Methylphenidate – attention deficit hyperactivity disorder” for the addition of methylphenidate to the list of the EMLc and EML for the treatment of children and adolescents between the ages of 6 to 17 years with attention deficit/hyperactivity disorder (ADHD). ADHD is one of the most common mental disorders in children and young people and the 39th leading cause of years lived with disability among those aged 5 to 14 years. The diagnosis is associated with poorer quality of life, worse educational attainment, and higher risk of unintentional injuries and death in childhood and adolescence. In the United States, methylphenidate is a known and well-regarded standard of care for ADHD, supported by decades of research, and part of the practice parameters for ADHD treatment of the American Academy of Child & Adolescent Psychiatry and the American Academy of Pediatrics.

Thank you for your consideration,



Richard R. Pleak, MD, DLFAACAP, DLFAPA

Senior Advisor, Child & Adolescent Psychiatry Fellowship; & Associate Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell  
Adjunct Associate Professor of Clinical Psychiatry & Behavioral Sciences,  
Albert Einstein College of Medicine